These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 37517427)
1. Assessment of corneal sublayer thickness changes in glaucoma patients using optical coherence tomography and correlation of epithelial layer thinning with dry eye monitoring. Eraslan N; Celikay O Photodiagnosis Photodyn Ther; 2023 Sep; 43():103728. PubMed ID: 37517427 [TBL] [Abstract][Full Text] [Related]
2. Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography. Eraslan N; Celikay O Int Ophthalmol; 2023 Sep; 43(9):3175-3184. PubMed ID: 37067694 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma. Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830 [TBL] [Abstract][Full Text] [Related]
4. Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye. Huang MJ; Samuelson TW; De Francesco T; Levin A; Sieck E; Gazzard G; Porter M; Gallardo M; Chang RT; Liu WW; Chaya C; Gulati S; Shah M J Cataract Refract Surg; 2023 Jul; 49(7):764. PubMed ID: 37390324 [TBL] [Abstract][Full Text] [Related]
5. Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study. Güçlü H; Çınar AK; Çınar AC; Akaray İ; Şambel Aykutlu M; Sakallıoğlu AK; Gürlü V Cutan Ocul Toxicol; 2021 Jun; 40(2):85-94. PubMed ID: 33719786 [TBL] [Abstract][Full Text] [Related]
6. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy. Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination. Alezzandrini A; Hubatsch D; Alfaro R Adv Ther; 2014 Sep; 31(9):975-85. PubMed ID: 25138224 [TBL] [Abstract][Full Text] [Related]
8. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262 [TBL] [Abstract][Full Text] [Related]
9. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465 [TBL] [Abstract][Full Text] [Related]
10. Anterior-Segment Optical Coherence Tomography and Scanning Electron Microscopy to Evaluate Corneal Epithelial Changes in Patients Undergoing Glaucoma Therapy. Cennamo G; Montorio D; Del Prete S; Del Prete A; Cennamo G Cornea; 2018 Dec; 37(12):1522-1526. PubMed ID: 30212410 [TBL] [Abstract][Full Text] [Related]
11. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. Frampton JE Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399 [TBL] [Abstract][Full Text] [Related]
12. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Hommer A; Kapik B; Shams N; Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402 [TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany. Thelen U; Buchholz P; Kimmich F Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. García-López A; Paczka JA; Jiménez-Román J; Hartleben C BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295 [TBL] [Abstract][Full Text] [Related]
15. Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucoma. Konstas AG; Quaranta L; Yan DB; Mikropoulos DG; Riva I; Gill NK; Barton K; Haidich AB Eye (Lond); 2012 Jan; 26(1):80-7. PubMed ID: 21960068 [TBL] [Abstract][Full Text] [Related]
16. A Comparative Study of Central Corneal Epithelial, Stromal, and Total Thickness in Males With and Without Primary Open-Angle Glaucoma. Batawi H; Lollett IV; Maliakal C; Wellik SR; Anderson MG; Feuer W; Karp CL; Galor A Cornea; 2018 Jun; 37(6):712-719. PubMed ID: 29553989 [TBL] [Abstract][Full Text] [Related]
17. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370 [TBL] [Abstract][Full Text] [Related]
18. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241 [TBL] [Abstract][Full Text] [Related]
19. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma. Cho SW; Kim JM; Park KH; Choi CY Jpn J Ophthalmol; 2010 Sep; 54(5):407-13. PubMed ID: 21052902 [TBL] [Abstract][Full Text] [Related]
20. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Motolko MA Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]